Andrew Last - Precigen COO
COO
Dr. Andrew J. Last, Ph.D. was appointed as Chief Operating Officer of the Company. Dr. Last joined Intrexon as our Chief Operating Officer in August 2016. Dr. Last brings to Intrexon 30 years of experience spanning life sciences, including biotechnology, genomics, clinical diagnostics, pharmaceuticals and agrochemicals, with several industry leading companies. Prior to joining Intrexon, Dr. Last served from January 2014 to July 2016 as the Executive Vice President and Chief Operating Officer of Affymetrix where he was responsible for directing five business units and overseeing strategic marketing, product management, RD, clinical operations, regulatory affairs, QAQC, and overall manufacturing operations for the company. From December 2009 to December 2013, Dr. Last served as the Executive Vice President and Chief Commercial Officer of Affymetrix directly managing global sales, product management, field marketing, service and support. Prior to joining Affymetrix, Dr. Last served as Vice President, Global Strategic Marketing of Becton Dickinson BioSciences Cell Analysis Division General Manager of Pharmingen, contributing as a member of the executive management team responsible for overall business strategy and execution, as well as driving development across a broad product portfolio. He has also held executive positions with Applied Biosystems and Incyte Genomics. Further, Dr. Last spent a significant tenure with Monsanto Company serving in numerous leadership positions including Director, Worldwide Business and Category Management, and Director, Ortho Home Garden, for the Solaris Group, as well as Manager, Innovation and Product Development, EuropeAfrica, for the Agricultural Group. He is currently a member of the Board of Directors of Oncocyte Corporation since 2016.
| Age | 56 |
| Tenure | 8 years |
| Phone | 301 556-9900 |
| Web | www.dna.com |
Andrew Last Latest Insider Activity
Tracking and analyzing the buying and selling activities of Andrew Last against Precigen stock is an integral part of due diligence when investing in Precigen. Andrew Last insider activity provides valuable insight into whether Precigen is net buyers or sellers over its current business cycle. Note, Precigen insiders must abide by specific rules, including filing SEC forms every time they buy or sell Precigen'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Andrew Last over a month ago Disposition of 430 shares by Andrew Last of Bio-Rad Laboratories at 4.6 subject to Rule 16b-3 |
Precigen Management Efficiency
Precigen's management efficiency ratios could be used to measure how well Precigen manages its routine affairs as well as how well it operates its assets and liabilities.The company has 260.44 M in debt with debt to equity (D/E) ratio of 114.0, demonstrating that the company may be unable to create cash to meet all of its financial commitments. Precigen has a current ratio of 1.88, which is typical for the industry and considered as normal. Debt can assist Precigen until it has trouble settling it off, either with new capital or with free cash flow. So, Precigen's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Precigen sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Precigen to invest in growth at high rates of return. When we think about Precigen's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 1 records | COO Age | ||
| Christopher Synek | Vestis | 57 | |
Management Performance
| Return On Equity | -1.52 | |||
| Return On Asset | -0.0059 |
Precigen Leadership Team
Elected by the shareholders, the Precigen's board of directors comprises two types of representatives: Precigen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Precigen. The board's role is to monitor Precigen's management team and ensure that shareholders' interests are well served. Precigen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Precigen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Steven Frank, Independent Director | ||
| Robert Walsh, Senior Vice President - Energy and Chemicals Sector | ||
| Thomas Kasser, Senior Vice President - Food Sector | ||
| Corey Huck, senior Vice President Food Sector | ||
| Gregory Frost, Sr. VP of Health Sector | ||
| Randal Kirk, Chairman of the Board, CEO | ||
| Andrew Last, COO | ||
| Christopher Basta, Vice President - Investor Relations | ||
| Rick Sterling, CFO | ||
| Krish Krishnan, COO | ||
| Cesar Alvarez, Independent Director | ||
| Donald Lehr, Chief Legal Officer | ||
| Joseph Vaillancourt, Senior Vice President Environment Sector | ||
| Jeffrey Perez, Senior Vice President — Intellectual Property Affairs | ||
| Joel Liffmann, Senior Vice President - Finance | ||
| Helen Sabzevari, President of Precigen, Inc. | ||
| Dean Mitchell, Independent Director | ||
| Robert Shapiro, Independent Director | ||
| Geno Germano, President | ||
| Jeffrey Kindler, Independent Director | ||
| Jack Bobo, Senior Vice President Chief Communications Officer | ||
| Ena Cratsenburg, Senior Vice President - Consumer Sector | ||
| Thomas Bostick, COO | ||
| Samuel Broder, Executive Vice President - Scientific and Public Affairs | ||
| Suma Krishnan, Senior Vice President - Product Development | ||
| Vinita Gupta, Director | ||
| Fred Hassan, Director | ||
| James Turley, Independent Director | ||
| Darryl Webster, Senior Vice President - Intellectual Property | ||
| Nir Nimrodi, Sr. VP of Corporate Devel. and Environment Sector | ||
| Thomas Reed, Founder and Chief Science Officer |
Precigen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Precigen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.52 | |||
| Return On Asset | -0.0059 | |||
| Profit Margin | (62.86) % | |||
| Operating Margin | (326.37) % | |||
| Current Valuation | 849.06 M | |||
| Shares Outstanding | 168.66 M | |||
| Shares Owned By Insiders | 16.01 % | |||
| Shares Owned By Institutions | 75.15 % | |||
| Number Of Shares Shorted | 33.33 M | |||
| Price To Earning | (16.30) X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Precigen in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Precigen's short interest history, or implied volatility extrapolated from Precigen options trading.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Current Watchlist to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Other Consideration for investing in Precigen Stock
If you are still planning to invest in Precigen check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Precigen's history and understand the potential risks before investing.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |